Fosamax and Osteonecrosis of the Jaw: Understanding Long-Term Prognosis

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health Information

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and treatment outcomes. Within this broad domain, the dissemination of knowledge regarding medication side effects and long-term prognosis has been a cornerstone, enabling patients and clinicians to make informed decisions. Historically, this framework has addressed a wide spectrum of conditions, from chronic diseases to acute interventions, without delving into the mechanistic details of specific pathologies. Transitioning from this general health context, a focused concern emerges regarding the occupational exposure to bisphosphonates, such as Fosamax, and the associated risk of osteonecrosis of the jaw. While the general health paradigm provides the baseline for understanding drug safety and patient outcomes, the occupational setting introduces distinct variables. Workers in pharmaceutical manufacturing, healthcare administration, or related fields may encounter prolonged or inadvertent exposure to these compounds, raising questions about long-term prognosis that differ from typical patient scenarios. This pivot necessitates a shift from broad health literacy to a targeted assessment of how occupational environments influence the trajectory of conditions like osteonecrosis of the jaw. The transition thus reframes the legacy of general information into a specialized inquiry, focusing on exposure contexts rather than disease mechanisms, while maintaining a neutral, evidence-informed perspective.

Bridging to Fosamax and ONJ

Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use is associated with a rare but serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ is characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ typically involves pain, swelling, and exposed bone in the mandible or maxilla, often following dental procedures. Diagnosis is based on clinical examination and imaging, with a focus on ruling out other causes of jaw necrosis.

Mechanisms and Risk Factors

The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast-mediated bone resorption. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress remodeling. This suppression can impair the ability of the jawbone to repair microdamage and respond to infection or trauma, leading to necrosis. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk of ONJ may increase with duration of exposure to bisphosphonates. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Prognosis and Long-Term Outcomes

The prognosis for patients who develop ONJ after Fosamax exposure varies. According to the drug label, the time to onset of symptoms varied from one day to several months after starting the drug. Most patients had relief of symptoms after stopping the medication. However, a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while discontinuation can lead to improvement, some patients may experience persistent or recurrent disease. The label advises to discontinue use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Long-term outcome data from observational studies provide additional context. A cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use. Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that while the relative risk increases with longer exposure, the absolute risk remains small, and prognosis improves after stopping the drug.

Adequacy of Warnings and Clinical Implications

Regarding the adequacy of warnings, the Fosamax label includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions." It notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors. The label also provides guidance on management, including discontinuation for severe symptoms and consideration of stopping treatment before invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also states that in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may limit the perceived risk. The timeline between exposure and documented harm is variable. Symptoms can appear from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer duration of use, as evidenced by the threefold increase after 2-3 years and eightfold increase after 10 years (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests that both short-term and long-term exposures carry risk, though the absolute risk remains low.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for osteonecrosis of the jaw after Fosamax exposure?

The prognosis is generally favorable with drug discontinuation, as most patients experience symptom relief. However, a subset may have recurrence upon rechallenge. Long-term outcomes are influenced by risk factors and duration of exposure. According to the drug label, most patients had relief of symptoms after stopping the medication, but some had recurrence when rechallenged (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study found that absolute risk remains low (approximately 0.05% after 5 years) and diminishes after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

How long after starting Fosamax can osteonecrosis of the jaw develop?

Symptoms can appear from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer duration of use, with a threefold increase after 2-3 years and eightfold increase after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk may increase with duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.